Clinical trial · Interventional
Β3-adrenoreceptor As Prognostic Marker in Neuroblastoma and Ewing Sarcoma
NCT06851221CI-TRIAL-00086652completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study on biological samples of patients affected by neuroblastoma and Ewing sarcoma aims at validating the beta3-adrenoreceptor as prognostic biomarker.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ewing Sarcoma | Ewing Sarcoma | ONTOLOGY_EXACT | 0.98 |
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| beta3 expression | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- biological samples analysis
- interventionNames
- Diagnostic Test: beta3 expression
Primary outcomes (1)
- measure
- expression of beta3-adrenoreceptor
- timeFrame
- from enrollment to the performance of the analysis that can take up to 6 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 0 Years
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosis of Ewing sarcoma or neuroblastoma Exclusion Criteria: * sieropositivity
References
Publications (0)
Data not yet available
No reference posted for this study.